Pavaki Capital Management LLC’s Cellebrite CLBT Stock Holding History

Pavaki Capital Management LLC’s Portfolio CLBT Stock Details CLBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$876K	Buy	+60,000	New	+$793K	0.31%	60

Other funds holding CLBT

TWCM

True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

MFAM

Motley Fool Asset Management Alexandria, Virginia $2.59B AUM 28.43% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Pavaki Capital Management LLC's CLBT Position: Q2 2026 in Review

Pavaki Capital Management LLC opened a new position in Cellebrite (CLBT) in Q2 2026: 60,000 shares worth $876K. The stake represents 0.31% of the portfolio and ranks #60 among its holdings.

69 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

Pavaki Capital Management LLC held 60,000 shares of Cellebrite worth $876K as of Q2 2026.
Cellebrite was a new Pavaki Capital Management LLC position in Q2 2026.
Cellebrite made up 0.31% of Pavaki Capital Management LLC's portfolio in Q2 2026, its #60 holding.
69 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on Pavaki Capital Management LLC's 13F filing for Q2 2026, filed 7 Aug 2026.